Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Viatris (VTRS) Receives a Hold from J.P. Morgan

Tipranks - Tipranks - Thu Feb 12, 6:26AM CST

J.P. Morgan analyst Chris Schott maintained a Hold rating on Viatris today and set a price target of $16.00.

Valentine's Day Sale - 70% Off

According to TipRanks, Schott is a 4-star analyst with an average return of 6.6% and a 57.98% success rate. Schott covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Gilead Sciences, and Pfizer.

In addition to J.P. Morgan, Viatris also received a Hold from TipRanks – Google’s Google Drug Manufacturers – Specialty and Generic in a report issued on February 4. However, on February 9, UBS upgraded Viatris (NASDAQ: VTRS) to a Buy.

See today’s best-performing stocks on TipRanks >>

Based on Viatris’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $3.76 billion and a GAAP net loss of $128.2 million. In comparison, last year the company earned a revenue of $3.75 billion and had a net profit of $94.8 million

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).